camizestrant
An orally available selective estrogen receptor degrader (SERD), with potential antineoplastic activity. Upon administration, camizestrant binds to the estrogen receptor (ER) and induces a conformational change that results in the degradation of the receptor. This prevents ER-mediated signaling and inhibits the growth and survival of ER-expressing cancer cells.
| Synonym: | N-(1-(3-fluoropropyl)-3-azetidinyl)-6-((6S,8R)-8-methyl-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3H-pyrazolo(4,3-f)isoquinolin-6-yl)-3-pyridinamine SERD AZD9833 |
|---|---|
| Code name: | AZ-14066724 AZD 9833 AZD-9833 AZD9833 |